Amgen Inc.

AMGN Healthcare Drug Manufacturers General

Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.

432.49 1.54 −0.35%
Market cap
$234.7B
P/E
26.7×
Fwd P/E
22.7×
Dividend yield
2.30%
F-score
7/9
Altman Z
1.69
Beneish M
−2.27
Dividend safety
56/100

Amgen Inc. (AMGN) Total debt

Alert me on Total debt

Amgen Inc.'s total debt at the end of fiscal 2025 was $54.6B, down 9.14% from $60.1B in fiscal 2024. At the end of the quarter to 30 June 2026 it was $57.3B. Over the past ten years it has ranged from $29.9B (fiscal 2019) to $64.6B (fiscal 2023); the current reading is higher than 82% of that period. Amgen Inc. ranks 3rd of 21 Drug Manufacturers General companies by total debt.

Total debt, annual

Embed this chart

Annual newest first

Period Total debt Change
FY2025 $54.6B (9.14%)
FY2024 $60.1B (6.99%)
FY2023 $64.6B 65.91%
FY2022 $38.9B 16.92%
FY2021 $33.3B 0.98%
FY2020 $33.0B 10.31%
FY2019 $29.9B (11.87%)
FY2018 $33.9B (4.00%)
FY2017 $35.3B 2.16%
FY2016 $34.6B 10.08%

Quarterly newest first

Period Total debt Change
Jun 2026 $57.3B (0.03%)
Mar 2026 $57.3B 4.98%
Dec 2025 $54.6B 0.03%
Sep 2025 $54.6B (2.88%)
42 more quarters

Against its own ten years

Low $29.9B High $64.6B
Ten-year median $34.6B
Current reading's percentile 82

Total debt against peers

What Total debt is

Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.

Long Term Debt (Total) + Current Part of Debt

The full definition of Total debt →

More on AMGN